<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The child with tall stature and/or abnormally rapid growth</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The child with tall stature and/or abnormally rapid growth</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The child with tall stature and/or abnormally rapid growth</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erick J Richmond, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan D Rogol, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Statural growth, a fundamental characteristic of childhood, is a complex process that is determined by the interaction of genetics, nutrition, and socioeconomic factors [<a href="#rid1">1</a>]. Regular assessment of growth is an essential part of pediatric practice and includes comparison of a child's growth pattern to established norms. When determining the normality of a child's growth pattern, serial measurements of height and calculation of height velocity (HV) is more useful than a single height-for-age percentile [<a href="#rid2">2</a>]. In interpreting a child's HV, allowance must be made for age, pubertal maturation, and other factors.</p><p>The causes, diagnosis, and treatment of children with abnormally rapid growth and tall stature will be reviewed here. The evaluation of children with short stature is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature"</a> and  <a class="medical medical_review" href="/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature"</a>.)</p><p class="headingAnchor" id="H3395992592"><span class="h1">BIOLOGY OF LINEAR GROWTH</span><span class="headingEndMark"> — </span>Emerging evidence reveals that normal and pathologic variations in linear growth depend on the balance between proliferation and senescence of chondrocytes at the growth plate. This process is regulated by many systems, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine mechanisms – Growth hormone (GH), insulin-like growth factor 1 (IGF-1), androgens, and thyroid hormone all stimulate chondrogenesis, while glucocorticoids inhibit chondrogenesis. Estrogens promote linear growth by stimulating GH and IGF-1 secretion, but also accelerate chondrocyte senescence, leading to fusion of the growth plates and cessation of linear growth [<a href="#rid3">3</a>]. As a result, estrogen deficiency or insensitivity (eg, caused by pathogenic variants in the estrogen receptor and aromatase genes), inhibits closure of the epiphyses, thus causing continued linear growth and tall stature. (See <a class="local">'Uncommon endocrine causes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proinflammatory cytokines – Some cytokines negatively regulate growth plate function. These are elevated in chronic inflammatory diseases, in which they slow linear growth and also growth plate senescence, which permits catch-up growth after the cytokine effect resolves [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paracrine mechanisms – Including fibroblast growth factors, bone morphogenetic proteins, parathyroid hormone-related protein, and others.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cartilage extracellular matrix – Includes collagens, proteoglycans, and other proteins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intracellular pathways – Chondrocyte transcription factors including <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F312865&amp;token=tEpDslnpc0F0kICl%2Fz7sFQyHoPb7eaMS7PXQVX%2BrKdyuCADFtVwIz6ECY84u%2FwNO&amp;TOPIC_ID=5848" target="_blank"><i>SHOX</i></a>, several <em>SOX</em> genes, and the MAPK signaling pathway. (See  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature", section on 'SHOX gene variants'</a>.)</p><p></p><p>Although many genetic alterations at the growth plate diminish growth (see  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature"</a>), several other genetic conditions promote linear growth. These include gain-of-function pathogenic variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F108961&amp;token=tEpDslnpc0F0kICl%2Fz7sFRc%2FQ%2FdLCs5TziGRc%2F5rLwiDZsukONtBrLRqqkA5A0iw&amp;TOPIC_ID=5848" target="_blank"><i>NPR2</i></a> [<a href="#rid6">6,7</a>] and loss-of-function variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F134934&amp;token=tEpDslnpc0F0kICl%2Fz7sFc6jRLzqNN8gxZwGEOirhGm3uXEPEcYfw51oqMl33e6u&amp;TOPIC_ID=5848" target="_blank"><i>FGFR3</i></a> that cause a syndrome characterized by camptodactyly (ie, bent finger that cannot be straightened), tall stature, and hearing loss (CATSHL) [<a href="#rid8">8,9</a>]. In addition, pathogenic variants that lead to alterations in epigenetic regulation are noted as the causes of Sotos syndrome, Weaver syndrome, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602769&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqyqoy48ImHzslyzoEoPrt%2B&amp;TOPIC_ID=5848" target="_blank"><i>DNMT3A</i></a> overgrowth syndrome [<a href="#rid10">10-13</a>]. Marfan syndrome is caused by certain pathogenic variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F134797&amp;token=tEpDslnpc0F0kICl%2Fz7sFc6jRLzqNN8gxZwGEOirhGnSOyae2y7hRWXasArNbkHo&amp;TOPIC_ID=5848" target="_blank"><i>FBN1</i></a>, whereas other variants in <em>FBN1</em> cause Weill-Marchesani syndrome, which includes short stature [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on '5q35 deletion syndrome (Sotos syndrome)'</a> and  <a class="medical medical_review" href="/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">EVALUATION OF CHILDREN AND ADOLESCENTS WITH TALL STATURE</span><span class="headingEndMark"> — </span>Although tall stature is as common as short stature, few children or their families seek medical attention for tall stature, presumably because it is socially acceptable and may be advantageous. Referrals for tall boys who are otherwise healthy are very rare. Referral for tall girls was common in the past but is now infrequent because of the increased social acceptance of tall girls and tall women in many societies.</p><p>Most children who grow excessively are part of a continuum of a normal distribution curve, and only a minority will have a defined abnormality of growth [<a href="#rid15">15-17</a>]. Nevertheless, it is important to identify children in whom tall stature or an accelerated growth rate is a symptom of an underlying disorder  (<a class="graphic graphic_table graphicRef94942" href="/d/graphic/94942.html" rel="external">table 1</a>).</p><p>Evaluation of a child suspected of having tall stature is guided by answering the following questions:</p><p class="bulletIndent1"><span class="glyph">●</span>Is the child's height abnormal for the population?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the child's growth abnormally rapid?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the child's growth within the range for the biologic family?</p><p class="bulletIndent1"><span class="glyph">●</span>Is there evidence of accelerated growth?</p><p></p><p>The answers to these questions guide a focused history and physical examination, and, in some cases, laboratory evaluation, to determine the cause and appropriate management [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H372147863"><span class="h2">Is the child's height abnormal for the population?</span><span class="headingEndMark"> — </span>Normal growth is defined by the variance of growth within the reference population. The normal range usually is defined as length or height within 2 standard deviations from the population mean (Z-score between -2 and +2). This threshold is equivalent to a height between the 2.3<sup>rd</sup> percentile and 97.7<sup>th</sup> percentile.</p><p>Tall stature is typically defined as length or height ≥97.7<sup>th</sup> percentile (Z-score ≥2) compared with the reference population. Less stringent definitions use length or height ≥95<sup>th</sup> percentile (Z-score ≥1.66). Height percentiles and Z-scores can be determined by plotting on a height-for-age chart or by using a calculator (<a class="calc calc_professional" href="/d/html/13413.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/d/html/13416.html" rel="external">calculator 2</a>). (See  <a class="medical medical_review" href="/d/html/5356.html" rel="external">"Measurement of growth in children", section on 'Length or height'</a>.)</p><p>For children with early puberty for their age, use of standard height-for-age references may exaggerate their degree of tall stature. For these children, growth potential may be more accurately assessed by using special Tanner stage-adjusted (TSA) growth standards, which are captured in this <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftsaheight2020.shinyapps.io%2Ftsa_height_clinical_calc_plotter_2020%2F&amp;token=BvRsvcUcobYlrMbMrM5Y5fuTPBwiuMCZgnBpgtFNCjA8%2Fkp4U49Ge9twc20cxeFGhGzSwt%2BV8oendDxTC1IWhd2pgclNl6WgvhGwSZxXDfY%3D&amp;TOPIC_ID=5848" target="_blank">online calculator</a> or by plotting the child's growth on a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fosf.io%2Fmyur7%2F&amp;token=g1M57B2GlJQWtUWPO%2FJkQa%2BXkrAifeWC4rAQav4cxM8%3D&amp;TOPIC_ID=5848" target="_blank">TSA-adjusted growth curve</a>, selected for their stage of pubertal maturation (sexual maturity rating) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H372147954"><span class="h2">Is the child's growth abnormally rapid?</span><span class="headingEndMark"> — </span>The second step in evaluating tall stature is determination of the child's growth rate or height velocity (HV). This requires serial measurements of height. Growth can be considered unusually rapid if:</p><p class="bulletIndent1"><span class="glyph">●</span>The height-for-age curve has deviated upward across two major height percentile curves (eg, from below the 75<sup>th</sup> percentile to above the 90<sup>th</sup> percentile) in children between two years of age and the onset of puberty  (<a class="graphic graphic_figure graphicRef63399 graphicRef77249" href="/d/graphic/63399.html" rel="external">figure 1A-B</a>). This pattern of growth reflects rapid height velocity, even if the patient has not developed tall stature. During the peripubertal period, height percentiles often increase for children who begin their pubertal growth spurt early then return to previous channels before their peers do the same.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Or, if the child is growing more rapidly than the following rates (which represent the 90<sup>th</sup> percentile for HV):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age two to four years – HV more than 9 cm/year (&gt;3.5 inches/year)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age four to six years – HV more than 8.5 cm/year (&gt;3.3 inches/year)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age six years to puberty:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>HV more than 6 cm/year for boys (&gt;2.4 inches/year)</p><p class="bulletIndent3"><span class="glyph">-</span>HV more than 6.5 cm/year for girls (&gt;2.6 inches/year)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For a more precise assessment of linear growth, the child's HV can be plotted on an HV chart  (<a class="graphic graphic_figure graphicRef96366 graphicRef96367" href="/d/graphic/96366.html" rel="external">figure 2A-B</a>) to determine the HV percentile for the child's age and sex.</p><p></p><p class="headingAnchor" id="H372149478"><span class="h2">Is the child's growth within the range for the family?</span><span class="headingEndMark"> — </span>The heights of the biologic parents reflect the genetic component for the child's growth. A general estimate of a child's genetic height potential can be obtained by calculation of the midparental height, which is based upon the heights of both parents and adjusted for the sex of the child. Whenever possible, the parents' heights should be directly measured rather than self-reported. The calculation can be performed using a calculator (<a class="calc calc_professional" href="/d/html/13422.html" rel="external">calculator 3</a>). This yields prediction of the child's adult height, sometimes called "target height". For both boys and girls, 8.5 cm (3.3 inches) on either side of this calculated value represents the 3<sup>rd</sup> to 97<sup>th</sup> percentiles for predicted adult height. (See  <a class="medical medical_review" href="/d/html/2845.html" rel="external">"Normal growth patterns in infants and prepubertal children", section on 'Predicted height'</a>.)</p><p>This method is substantially less accurate than the bone-age based method described below because it does not reflect disease processes or environmental contributions to growth, which may affect skeletal maturation. (See <a class="local">'Bone age'</a> below.)</p><p class="headingAnchor" id="H372149510"><span class="h2">Is there evidence of accelerated growth?</span><span class="headingEndMark"> — </span>For children with abnormally rapid HV, and especially those whose anticipated adult height is tall for the biologic family, we suggest determination of bone age.</p><p class="headingAnchor" id="H372149722"><span class="h3">Bone age</span><span class="headingEndMark"> — </span>Bone age is a measure of skeletal maturity, obtained by assessing the appearance and shape of the growth plates and bones of the left hand and wrist from a radiograph; this requires expert interpretation by a radiologist or endocrinologist with experience in the technique. The results can be used to inform estimates of the child's growth potential and likely adult height.</p><p>The bone age also helps to determine the differential diagnosis for the child's rapid growth. Most endocrine causes of tall stature are associated with advanced bone age, except for sex hormone deficiency or insensitivities, which are associated with delayed bone age. By contrast, familial tall stature usually is associated with normal bone age. (See <a class="local">'Statural overgrowth in infancy'</a> below and <a class="local">'Statural overgrowth in childhood and adolescence'</a> below.)</p><p class="headingAnchor" id="H372149817"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The child's pattern of growth, medical history (including detailed family history), and physical examination are the mainstays of assessment of tall and/or rapidly growing children. When dysmorphic features are found, special effort should be made to rule out the disorders and syndromes that are associated with excessive growth, including referral to an appropriate subspecialist, if available. Features that suggest a specific cause of overgrowth are outlined in the table and detailed below  (<a class="graphic graphic_table graphicRef94942" href="/d/graphic/94942.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H6"><span class="h1">STATURAL OVERGROWTH IN INFANCY</span><span class="headingEndMark"> — </span>Accelerated growth occurring during fetal life and infancy has several causes.</p><p class="headingAnchor" id="H7"><span class="h2">Maternal diabetes mellitus</span><span class="headingEndMark"> — </span>Maternal diabetes mellitus is the most common cause of large-for-gestational age infants. As an example, a population-based study of infants born to mothers with type 1 diabetes showed that 47 percent were large for gestational age, defined as weight greater than 90<sup>th</sup> percentile [<a href="#rid19">19</a>]. Maternal hyperglycemia leads to fetal hyperglycemia, which in turn causes fetal hyperinsulinemia. The hyperinsulinemia results in increased fetal growth, an increase in subcutaneous tissue, and enlargement of most organs, including the liver. Affected infants usually are large, more so in weight than in length [<a href="#rid20">20</a>]. Because of hyperinsulinemia, infants of diabetic mothers should be monitored for hypoglycemia during the first hours and days of life [<a href="#rid21">21</a>]. The hyperinsulinemia is transient, so this condition does not in itself cause overgrowth in infancy or childhood. However, there is an association between macrosomia at birth caused by maternal diabetes and later development of obesity. (See  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Cerebral gigantism</span><span class="headingEndMark"> — </span>Infants with cerebral gigantism (Sotos syndrome, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F117550&amp;token=87jLzclRwWxNoI%2BQq5Gg71rPI%2FO9hPnU0IL2nlvGn1gHgzsj5dp5FQIGwXWWMes8&amp;TOPIC_ID=5848" target="_blank">MIM #117550</a>) tend to be large at birth and continue to grow rapidly during the early years of childhood. Puberty usually occurs early in these children, resulting in premature epiphyseal fusion and, hence, adult height is normal in many of these children [<a href="#rid22">22,23</a>]. Thus, intervention usually is not needed. Distinctive dysmorphic features include macrocephaly, high forehead, frontal bossing, hypertelorism, prominent jaw, high arched palate, intellectual disability, and poor coordination. Most affected children have advanced bone age. Growth hormone secretion and serum insulin-like growth factor 1 (IGF-1) concentrations are normal. Most patients have intellectual disability; in a study of 52 patients with Sotos syndrome, the mean intelligence quotient score was 61, with a standard deviation of 17 [<a href="#rid24">24</a>].</p><p>The syndrome is sporadic in most cases, although some familial cases segregating in an autosomal dominant pattern have been described. Pathogenic variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606681&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqT1TJ%2BlRE4I2smzNOemVPN&amp;TOPIC_ID=5848" target="_blank"><i>NSD1</i></a> gene have been identified in the majority of individuals with Sotos syndrome [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on '5q35 deletion syndrome (Sotos syndrome)'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Beckwith-Wiedemann syndrome</span><span class="headingEndMark"> — </span>Infants with the Beckwith-Wiedemann syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F130650&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FU8bDEOj7%2BVX4ijIhuvOLFADHDwBepb25w3PQQ%2B%2FY6Q&amp;TOPIC_ID=5848" target="_blank">MIM #130650</a>) have a growth pattern similar to that of children with cerebral gigantism [<a href="#rid26">26</a>]. Affected children are tall and have advanced bone age and rapid growth during early childhood, which then slows; adult height is above the range predicted for the family [<a href="#rid27">27</a>]. Cardinal features present in most patients are macroglossia, abdominal wall defects (eg, omphalocele), macrosomia, ear creases/pits, organomegaly, neonatal hyperinsulinemic hypoglycemia, lateralized overgrowth, and risk for embryonal tumors including hepatoblastoma, neuroblastoma, and Wilms tumor [<a href="#rid28">28,29</a>]. Overexpression of insulin-like growth factor 2 (IGF-2) is probably an important determinant of the phenotype, although there are other growth-regulatory genes in the region that may also participate [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/13555.html" rel="external">"Beckwith-Wiedemann syndrome"</a> and  <a class="medical medical_review" href="/d/html/5053.html" rel="external">"Pathogenesis, screening, and diagnosis of neonatal hypoglycemia"</a>.)</p><p class="headingAnchor" id="H58039214"><span class="h2">Other overgrowth syndromes</span><span class="headingEndMark"> — </span>In addition to cerebral gigantism described above, other syndromes that are associated with generalized overgrowth include Perlman syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F267000&amp;token=87jLzclRwWxNoI%2BQq5Gg77zXznuWV1Dyf1WLSCu63kyNQrNVfRk0jOfqRA72P74%2B&amp;TOPIC_ID=5848" target="_blank">MIM #267000</a>), Simpson-Golabi-Behmel syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F312870&amp;token=87jLzclRwWxNoI%2BQq5Gg7yRv42XxHU%2FCdCJARhrwCPMjsBN%2FIIC%2BvEpZV2Q%2FqzvK&amp;TOPIC_ID=5848" target="_blank">MIM #312870</a>), Weaver syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F277590&amp;token=87jLzclRwWxNoI%2BQq5Gg77C4zg5qD4fw4ygMxSzxQSX4tTdUm6ILITwrSSxci9nn&amp;TOPIC_ID=5848" target="_blank">MIM #277590</a>), Marshall-Smith syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602535&amp;token=87jLzclRwWxNoI%2BQq5Gg74RDm7x7u%2FeNCDAFnI11W2hc6rVIff%2Fnk8w2w7qDokMF&amp;TOPIC_ID=5848" target="_blank">MIM #602535</a>), Malan syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614753&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5XinX8QYimCgrcRohyK496&amp;TOPIC_ID=5848" target="_blank">MIM #614753</a>) [<a href="#rid31">31</a>], and Gorlin syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F109400&amp;token=87jLzclRwWxNoI%2BQq5Gg7wZhcaiuBwPB8L%2FtD%2Fk%2ByeBuIFOkKhoXYvObxfkDnDzf&amp;TOPIC_ID=5848" target="_blank">MIM #109400</a>) [<a href="#rid32">32</a>].</p><p>In addition to Beckwith-Wiedemann syndrome described above, syndromes that are associated with segmental (patchy) overgrowth include isolated hemihyperplasia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F235000&amp;token=87jLzclRwWxNoI%2BQq5Gg76ElyxicjfX%2B3xGmU1RRgTYeFOi1eaidgnYItH%2BHh2hD&amp;TOPIC_ID=5848" target="_blank">MIM %235000</a>), CLOVE syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F612918&amp;token=87jLzclRwWxNoI%2BQq5Gg7xOue8zCena2M8nh1PLF6fnnrEgzDiL%2FZFs%2FOTbpOywE&amp;TOPIC_ID=5848" target="_blank">MIM #612918</a>), and Klippel-Trenaunay syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F149000&amp;token=87jLzclRwWxNoI%2BQq5Gg7wfPVAhpn3zjVBwekJNe%2F9DKcX1kkUHsUnBQYHg%2BrWXU&amp;TOPIC_ID=5848" target="_blank">MIM %149000</a>) (see  <a class="medical medical_review" href="/d/html/13726.html" rel="external">"Capillary malformations (port wine birthmarks) and associated syndromes", section on 'Associated syndromes'</a>); as well as segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome and Proteus syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F176920&amp;token=87jLzclRwWxNoI%2BQq5Gg78leWeAoTpRqnvPyR38qzsQxd%2FIQ85x6bBDGDH7pNqAg&amp;TOPIC_ID=5848" target="_blank">MIM #176920</a>). (See  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Proteus-like syndrome'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">STATURAL OVERGROWTH IN CHILDHOOD AND ADOLESCENCE</span><span class="headingEndMark"> — </span>Accelerated growth occurring in childhood or adolescence can result from familial factors as well as both endocrine and nonendocrine disorders. Endocrine causes can involve hormone excess, deficiency, or resistance.</p><p class="headingAnchor" id="H69599654"><span class="h2">Normal variant of growth</span></p><p class="headingAnchor" id="H69599708"><span class="h3">Familial tall stature</span><span class="headingEndMark"> — </span>Familial tall stature, also known as constitutional tall stature, is a variant of the normal pattern of childhood growth and development. It is defined as a condition in which the height of an individual is 2 standard deviations above the corresponding mean height for same age and sex in the population, in the absence of pathologic causes of tall stature [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H69600005"><span class="h4">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of familial tall stature is established by a family history of tall stature and lack of dysmorphic features, which permits distinction from the syndromes of excessive growth. These children usually have a height velocity in the high-normal range (around 6 cm/year between six years and puberty). The bone age is normal and may be used to predict adult stature. (See <a class="local">'Bone age'</a> above.)</p><p class="headingAnchor" id="H69599810"><span class="h4">Treatment</span><span class="headingEndMark"> — </span>Medical treatment of children and adolescents with familial tall stature was common in the past, particularly for girls, but is now strongly discouraged except in extreme cases [<a href="#rid33">33,34</a>]. This is because of increased cultural acceptance of tall stature and recognition of side effects of treatment, which include reduced fertility [<a href="#rid35">35</a>] and increased prevalence of depression not related to adult height [<a href="#rid36">36</a>]. The data presented below come from studies of children with familial tall stature, but they may be applicable to other causes of rapid growth in which the underlying disorder cannot be corrected.</p><p>Psychosocial problems in tall adolescent girls and boys have been recognized by pediatricians and endocrinologists, and in the past these were often used as a rationale for treatment [<a href="#rid37">37-39</a>]. However, dissatisfaction with treatment is common among girls who were treated for tall stature. In one study, more than 40 percent of treated women were dissatisfied with their (or their parent's) decision to assess and treat [<a href="#rid40">40</a>]. Dissatisfaction was related to the patient not having an active role in the decision-making, negative experiences with the assessment or treatment procedures, side effects of therapy, or late complications that women believed were associated with the therapy.</p><p>Sex steroids have been used in the treatment of tall boys and girls since the late 1950s. The goal is to promote premature epiphyseal fusion [<a href="#rid41">41,42</a>]. Estrogen causes epiphyseal fusion in both girls and boys [<a href="#rid43">43,44</a>]. The effects of steroid hormones on bone maturation are caused by an indirect action mediated by the growth hormone-IGF-1 axis, combined with a direct effect on the epiphyses [<a href="#rid45">45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogens</strong> – For treatment of tall girls, estrogen in the form of <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> or ethinyl estradiol, was used relatively frequently starting in the 1950s and peaking in the 1990s [<a href="#rid46">46</a>]. Treatment was usually started when the patient's bone age was between 10 and 12 years, and always before a bone age of 14 to 15 years [<a href="#rid47">47</a>]. The earlier the intervention, the more likely that adult height would be decreased [<a href="#rid47">47</a>]. Treatment was continued until the epiphyses fused because post-treatment growth may be substantial if cessation is premature.</p><p></p><p class="bulletIndent1">The following considerations should guide treatment decisions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The mean adjusted height reduction after estrogen treatment varies from 1.1 to 2.4 cm, and ranges vary from -2.6 cm to 6.2 cm [<a href="#rid48">48,49</a>], significantly less than previously claimed [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Estrogen side effects include nausea, weight gain, edema, and hypertension; other potential problems, such as thromboembolism and endometrial hyperplasia, have not been definitely related to estrogen therapy in children but also should be discussed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Estrogen treatment during adolescence may have a negative impact on later fertility [<a href="#rid50">50,51</a>]. This was illustrated in a study of 1243 adult women with hereditary tall stature, 310 of whom had been treated with estrogen as adolescents [<a href="#rid35">35</a>]. After adjustment for age, those who had received estrogen had an increased risk of infertility (inability to conceive after 12 months of trying; relative risk [RR] 1.8, 95% CI 1.4-2.3) and had lower fecundity (40 percent less likely to conceive in any given menstrual cycle of unprotected intercourse) when compared with those who had not received estrogen therapy. There were no differences in the distribution of infertility diagnoses between the estrogen-treated and untreated groups, and the mechanism for the increase in risk is unknown. (See  <a class="medical medical_review" href="/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgens</strong> – Androgens also accelerate epiphyseal fusion, presumably via aromatization to estrogens [<a href="#rid17">17</a>]. Although <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> can be given as treatment of constitutional tall stature in boys, its use for this purpose is extremely uncommon and not without risk. Usually, it is given in the form of a long-acting intramuscular testosterone ester, mean dose 500 mg/m<sup>2</sup> per month. In clinical practice, 500 mg every two weeks, or 250 mg every one or two weeks are used [<a href="#rid17">17,52</a>]. It is more effective if started when the bone age is less than 14 to 15 years of age and can increase growth if started at older bone ages [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epiphysiodesis</strong> – Percutaneous epiphysiodesis is a surgical damage of the growth plates of the tibia and femur under general anesthesia with a small surgical drill, with the purpose of restriction of excessive growth in very tall boys and girls. In a study of 77 Dutch adolescents, treatment with this procedure resulted in a 7.0 cm (± 6.3 cm) reduction in adult height compared with predicted height in boys and a 5.9 cm (± 3.7 cm) reduction in adult height in girls [<a href="#rid53">53</a>]. Short-term complications were reported in 5.1 percent and long-term complications in 2.6 percent of treated patients. This treatment option should be considered only in very tall patients, if a surgeon with appropriate experience with this procedure is available and if the patient and their family understand that data are limited and that it is not possible to predict a positive outcome in an individual patient.</p><p></p><p class="headingAnchor" id="H69598931"><span class="h2">Endocrine disorders</span></p><p class="headingAnchor" id="H11"><span class="h3">Precocious puberty</span><span class="headingEndMark"> — </span>Sexual precocity is much more common in girls than boys. It can be central (also known as gonadotropin-dependent precocious puberty) or peripheral (also known as gonadotropin-independent precocious puberty) [<a href="#rid54">54</a>]. In both cases, linear growth is accelerated during childhood, often with markedly advanced bone maturation. This results in the paradox of the tall child who, because of very early epiphyseal closure, will be short as an adult. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty"</a>.)</p><p>Central precocious puberty is either idiopathic or secondary to a central nervous system abnormality. Peripheral precocious puberty may be caused by congenital adrenal hyperplasia, virilizing adrenal, testicular and ovarian tumors, ovarian cysts, testotoxicosis (familial male-limited precocious puberty), McCune-Albright syndrome, human chorionic gonadotropin-secreting tumors (in males) and, rarely, longstanding severe primary hypothyroidism (Van Wyk-Grumbach syndrome). (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Causes of central precocious puberty'</a> and  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Causes of peripheral precocity'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Hyperthyroidism</span><span class="headingEndMark"> — </span>Hyperthyroidism caused by endogenous overproduction of thyroid hormones or overtreatment with exogenous thyroxine may lead to increased growth and advanced bone age; if endogenous or exogenous hyperthyroidism occurs during infancy, it may lead to craniosynostosis [<a href="#rid55">55</a>]. Treatment restores euthyroidism and normalizes the growth rate, leading to "catch-down" growth. As a result, the tall stature and transient increase in linear growth that occurs while the child is hyperthyroid usually do not require separate intervention. (See  <a class="medical medical_review" href="/d/html/5841.html" rel="external">"Clinical manifestations and diagnosis of Graves disease in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5839.html" rel="external">"Evaluation and management of neonatal Graves disease"</a>.)</p><p class="headingAnchor" id="H3000680436"><span class="h3">Uncommon endocrine causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex hormone deficiency or insensitivity</strong> – Permanent hypogonadism, that is, permanent deficiency of <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> in males or of estrogen in females, results in delayed skeletal maturation, a prolonged period of growth, and tall stature with eunuchoid proportions (long legs, diminished upper-lower segment ratio, and low sitting height compared with height). As an example, case reports describe several male patients with estrogen deficiency resulting from aromatase deficiency or estrogen resistance caused by a pathogenic variant of the estrogen receptor gene. These individuals had incomplete epiphyseal closure and extreme tall stature, as well as osteopenia [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/d/html/7403.html" rel="external">"Evaluation and management of primary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth hormone excess</strong> – Excessive growth hormone secretion causes gigantism in growing children and acromegaly after fusion of the epiphyses, usually in adults. Although rare in children, the possibility of gigantism should be considered when the height exceeds +3 to +4 standard deviations (&gt;99.9<sup>th</sup> percentile) [<a href="#rid56">56</a>]. Bone age is normal or may be delayed if the adenoma interferes with pituitary secretion of gonadotropins. (See  <a class="medical medical_review" href="/d/html/5855.html" rel="external">"Pituitary gigantism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial glucocorticoid deficiency </strong>– Familial glucocorticoid deficiency is a grouping of rare autosomal recessive disorders characterized by hypoglycemia, seizures, and increased skin pigmentation. The type 1 form (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F202200&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bEqSr%2FY5c1mwphbnJ3xtJtS&amp;TOPIC_ID=5848" target="_blank">MIM #202200</a>) is also associated with tall stature or advanced bone age and clinical manifestations of adrenal insufficiency and is caused by pathogenic variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607397&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyryNGRkAqs6mBmE%2FTMfpSvT&amp;TOPIC_ID=5848" target="_blank"><i>MC2R</i></a> [<a href="#rid57">57-60</a>]. The type 2 form is caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609196&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE%2FZsdyCnuOa5GkHrxyWKQQ&amp;TOPIC_ID=5848" target="_blank"><i>MRAP</i></a> gene and is not associated with tall stature [<a href="#rid61">61</a>]. Biochemical findings in both forms include extremely high plasma adrenocorticotropic hormone (ACTH) concentrations, together with low or undetectable serum cortisol concentrations that do not increase in response to exogenous ACTH stimulation. (See  <a class="medical medical_review" href="/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Familial glucocorticoid deficiency'</a>.)</p><p></p><p class="bulletIndent1">Excessive production of adrenal androgens probably is responsible for the tall stature. Another suggestion is that the high plasma ACTH concentrations may activate melanocyte-stimulating hormone receptors in cartilaginous growth plates and that the increase in height is caused by the unopposed anabolic action of growth hormone [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial glucocorticoid resistance</strong> – Familial glucocorticoid resistance (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615962&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7mpU2Ji%2Ba52or3GctXzDAR&amp;TOPIC_ID=5848" target="_blank">MIM #615962</a>, also known as generalized glucocorticoid resistance) is caused by variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F138040&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiumtWUo8j5jcDSo0kB%2FAvksa&amp;TOPIC_ID=5848" target="_blank"><i>NR3C1</i></a> gene. It is a rare cause of hypercortisolism but may lead to excessive growth because the resistance leads to increased ACTH levels, which may then stimulate adrenal androgen production and generalized hyperpigmentation. The disorder presents in females with hirsutism, male pattern baldness, menstrual abnormalities, and infertility, and presents in males with isosexual precocious puberty, abnormal spermatogenesis, and infertility. Because this is a form of peripheral precocity, the testes are relatively small compared with the degree of growth and virilization. The bone age is advanced and many individuals who are quite tall during childhood and adolescence do not become unusually tall adults [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/5806.html" rel="external">"Premature adrenarche", section on 'Other hyperandrogenic causes of premature pubarche'</a> and  <a class="medical medical_review" href="/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Glucocorticoid resistance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital total lipodystrophy</strong> – Congenital total lipodystrophy (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608594&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHULfne5zxCjH20pdun1%2BM3&amp;TOPIC_ID=5848" target="_blank">MIM #608594</a> and others) is a rare autosomal recessive disorder. The diagnosis can be based on clinical criteria, but genetic testing is the gold standard [<a href="#rid63">63</a>]. The main clinical features, in addition to overgrowth and acromegaloid changes, are generalized absence of subcutaneous fat, muscular hypertrophy, hyperpigmentation, enlargement of the penis or clitoris, advanced bone age, insulin resistance, hyperinsulinemia, hyperlipidemia, and nonketotic hyperglycemia [<a href="#rid64">64,65</a>]. Large doses of insulin are given to avoid decompensation, but normoglycemia may not be attainable. Adult height in these patients tends to be normal or tall [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/1788.html" rel="external">"Lipodystrophic syndromes", section on 'Congenital generalized lipodystrophy'</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Nonendocrine disorders</span></p><p class="headingAnchor" id="H19"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>Common obesity (ie, not syndromic or monogenic) may be accompanied by modest overgrowth and early onset of puberty, especially in girls [<a href="#rid67">67</a>]. These children usually have diminished overall growth hormone production but normal serum concentrations of insulin-like growth factor 1 (IGF-1) and IGF binding proteins, typically in conjunction with tall stature for age prior to puberty. However, bone age may be advanced and puberty may start early, causing premature epiphyseal fusion so that adult height is not increased. These adolescents often attain normal adult height unless puberty starts unusually early, in which case they may not reach their midparental target height [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity"</a>.)</p><p class="headingAnchor" id="H563515450"><span class="h3">Melanocortin 4 receptor pathogenic variant</span><span class="headingEndMark"> — </span>Children with obesity due to pathogenic variants in the melanocortin 4 receptor (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F618406&amp;token=tEpDslnpc0F0kICl%2Fz7sFbbHsBJVAXU52QtjSlxi7cU30%2FeCb9uv26PZZl1Gqe0i&amp;TOPIC_ID=5848" target="_blank">MIM #618406</a>), which is the most common monogenic cause of obesity in humans, also tend to have increased liner growth [<a href="#rid69">69,70</a>]. This results in height that is taller than predicted from their obesity alone. Possible mechanisms include an increase in growth hormone pulsatility, which contrasts to the decreased level seen in exogenous obesity, and an increase in insulin secretion. (See  <a class="medical medical_review" href="/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology", section on 'Heritable factors'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Klinefelter syndrome</span><span class="headingEndMark"> — </span>Klinefelter syndrome is caused by an abnormality in chromosome number in which two or more X chromosomes are present in phenotype males [<a href="#rid71">71</a>]. The most common abnormal karyotype is 47,XXY. Prepubertal boys often are tall for their age with relatively long legs compared with the trunk, and they may have learning disabilities, mainly in expressive language. Small testes and gynecomastia are the most common features on physical examination during adolescence. Other genital abnormalities may be present, such as small phallus, hypospadias, and cryptorchidism. Almost all boys enter puberty but there is marked heterogeneity in the degree of virilization. Bone age may be normal or delayed, depending on the level of <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> secretion. (See  <a class="medical medical_review" href="/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males", section on 'Klinefelter syndrome'</a> and  <a class="medical medical_review" href="/d/html/6583.html" rel="external">"Hypospadias: Pathogenesis, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/610.html" rel="external">"Specific learning disorders in children: Clinical features", section on 'Risk factors'</a>.)</p><p>Serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations are typically normal in prepubertal children with Klinefelter syndrome, but are often high in adolescents and adults. Usually, serum <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> concentrations are in the low normal adult range. Testosterone treatment can be initiated during the pubertal years to facilitate development of secondary sexual characteristics and minimize the psychologic complications of hypogonadism [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H21"><span class="h3">47,XYY (Jacobs) syndrome</span><span class="headingEndMark"> — </span>Boys with a 47,XYY karyotype tend to have tall stature and mild problems in motor and language development [<a href="#rid73">73</a>]. Adults with this syndrome are tall, have large teeth, radioulnar synostosis, clinodactyly, tremor, incoordination, and sometimes neurodevelopmental problems including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders [<a href="#rid74">74</a>]. No treatment for the tall stature is required, unless desired by the patient. (See  <a class="medical medical_review" href="/d/html/16974.html" rel="external">"Sex chromosome abnormalities", section on '47,XYY syndrome'</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Marfan syndrome</span><span class="headingEndMark"> — </span>Marfan syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F154700&amp;token=87jLzclRwWxNoI%2BQq5Gg7yQ37FL9KKynuz3N1sECre8NYOBVhdZtsT7859AcFrAF&amp;TOPIC_ID=5848" target="_blank">MIM #154700</a>) is an autosomal dominant abnormality of connective tissue characterized by tall stature, long, thin fingers (arachnodactyly), disproportionately long arms compared with the trunk (dolichostenomelia), hyperextension of joints, and lens subluxation, usually in the upward and outward direction. Pectus excavatum, scoliosis, aortic or mitral regurgitation, and aortic root dilatation may be present. Bone age usually is normal. Female and male patients with this syndrome may attain excessively tall height, and treatment with estrogen in women and <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> in men may be indicated, especially if any orthopedic problem is present. (See  <a class="medical medical_review" href="/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p>The basic defect in Marfan syndrome has been traced to an altered fibrillin gene (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F134797&amp;token=87jLzclRwWxNoI%2BQq5Gg733rEkupSJBwyjmdGKVAif4ZynpBGzDQ1eTFAwkg7nXQ&amp;TOPIC_ID=5848" target="_blank"><i>FBN1</i></a>) on chromosome 15q21.1 [<a href="#rid75">75,76</a>]. Fibrillin is a connective tissue protein found in microfibrils, a constituent of elastic tissue; these microfibrils are abundant in affected tissues [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Homocystinuria</span><span class="headingEndMark"> — </span>Classic homocystinuria (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F236200&amp;token=87jLzclRwWxNoI%2BQq5Gg78r%2B6SHAuT4sR9mAX3OLP1x%2Fk3cUToqV5%2BULTNRg5oCc&amp;TOPIC_ID=5848" target="_blank">MIM #236200</a>) is an inherited inborn error of methionine metabolism caused by a deficiency of the enzyme cystathionine synthetase [<a href="#rid77">77,78</a>]. Some of the clinical features are similar to those of Marfan syndrome, with subluxation of the lens being the most consistent finding, although the direction of subluxation is usually downward and inward. (See  <a class="medical medical_review" href="/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a> and  <a class="medical medical_review" href="/d/html/6264.html" rel="external">"Ectopia lentis (dislocated lens) in children", section on 'Genetic causes'</a>.)</p><p>Fifty percent of patients with homocystinuria have intellectual disability. Life-threatening thromboembolic phenomena may occur at any age, and early onset of osteoporosis is seen [<a href="#rid79">79</a>]. A subset of patients respond to treatment with <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">pyridoxine</a> (vitamin B6); a methionine-restricted diet also may be helpful [<a href="#rid80">80</a>]. No treatment for the tall stature is recommended.</p><p class="headingAnchor" id="H24"><span class="h3">Neurofibromatosis type 1</span><span class="headingEndMark"> — </span>Neurofibromatosis type 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F162200&amp;token=87jLzclRwWxNoI%2BQq5Gg77pEMQ1kNomdpMkCUrjQ8Moy%2FjwSXEVVB59TjgXXQowy&amp;TOPIC_ID=5848" target="_blank">MIM #162200</a>) is an autosomal dominant disorder that comprises at least 85 percent of all cases of neurofibromatosis [<a href="#rid81">81</a>]. It is caused by an abnormality of neural crest differentiation and migration during the early stages of embryogenesis. This disorder is linked to the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613113&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2F%2BKFe2jxUfZjVSjXMKZ04t6GaZjRBiynwafdLQh0ceA&amp;TOPIC_ID=5848" target="_blank"><i>NF1</i></a> gene that encodes neurofibromin, a protein that normally restricts cell proliferation. (See  <a class="medical medical_review" href="/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Short stature is common (as a result of precocious puberty), but rare patients are excessively tall who have otherwise unexplained dysregulated growth hormone secretion [<a href="#rid82">82,83</a>]. Thus, neurofibromatosis should be considered in patients with overgrowth.</p><p class="headingAnchor" id="H1049414931"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114455.html" rel="external">"Society guideline links: Growth hormone deficiency and other growth disorders"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Tall stature is defined as length or height ≥97.7<sup>th</sup> percentile (Z-score ≥2) for the population. Less stringent definitions use length or height ≥95<sup>th</sup> percentile (Z-score ≥1.66). Height percentiles and Z-scores can be determined by plotting on a height-for-age chart  (<a class="graphic graphic_figure graphicRef63399 graphicRef77249" href="/d/graphic/63399.html" rel="external">figure 1A-B</a>) or calculated using a calculator for standing height for boys (<a class="calc calc_professional" href="/d/html/13413.html" rel="external">calculator 1</a>) or for girls (<a class="calc calc_professional" href="/d/html/13416.html" rel="external">calculator 2</a>). Abnormally rapid growth is suggested if a child's height has deviated upward across two major height percentile curves between two years of age and the onset of puberty. (See <a class="local">'Is the child's height abnormal for the population?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Height velocity</strong> – Calculation of height velocity (HV) is an important step in the assessment of a child with tall stature. HV above the following thresholds usually is abnormal and should prompt an evaluation for a growth abnormality:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age two to four years – HV more than 9 cm/year (&gt;3.5 inches/year)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age four to six years – HV more than 8.5 cm/year (&gt;3.3 inches/year)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age six years to puberty:</p><p></p><p class="bulletIndent3">HV more than 6 cm/year for boys (&gt;2.4 inches/year)</p><p class="bulletIndent3">HV more than 6.5 cm/year for girls (&gt;2.6 inches/year)</p><p></p><p class="bulletIndent2">For a more precise assessment of linear growth, the child's HV can be plotted on an HV chart  (<a class="graphic graphic_figure graphicRef96366 graphicRef96367" href="/d/graphic/96366.html" rel="external">figure 2A-B</a>) to determine the HV percentile for the child's age and sex; an HV greater than the 90<sup>th</sup> percentile is considered abnormal. (See <a class="local">'Is the child's growth abnormally rapid?'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Height prediction</strong> – A general estimate of a child's genetic height potential can be obtained by calculation of the midparental height, which is based upon the heights of both biologic parents and adjusted for the sex of the child. The calculation can be performed using an equation or calculator (<a class="calc calc_professional" href="/d/html/13422.html" rel="external">calculator 3</a>). A tall child whose height is within the range expected for the biologic family is likely to have familial tall stature. (See <a class="local">'Is the child's growth within the range for the family?'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone age determination</strong> – For children with abnormally rapid HV, and especially those whose projected height is tall for the biologic family, the evaluation for tall stature should also include radiographic determination of bone age. This result is used to predict height potential. This provides a more accurate estimate of the child's adult height than the midparental height method. It also identifies delayed or accelerated skeletal growth, which may be associated with certain endocrine disorders. (See <a class="local">'Bone age'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of tall stature</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Familial tall stature</strong> – Familial (constitutional) tall stature, a variant of the normal pattern of childhood growth and development, is defined as a condition in which the height of an individual is more than 2 standard deviations above the corresponding mean height for a normal subject of the same age and sex, in the absence of pathologic causes of tall stature. Distinguishing features are a family history of tall stature and lack of dysmorphic features, which permits distinction from pathologic causes of excessive growth. We do <strong>not</strong> recommend medical treatment for most children with familial tall stature (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>), because there is little evidence of psychosocial benefits and because of possible adverse effects, including increased risks for infertility. (See <a class="local">'Familial tall stature'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathologic causes</strong> – The possibility of a disorder causing rapid growth should be considered in children with abnormal HV (as defined above), or in any child with rapid growth and features suggestive of an underlying disorder, including dysmorphic features, disproportionate growth (eg, long arms or legs compared with the trunk), precocious puberty or hypogonadism, or developmental delay  (<a class="graphic graphic_table graphicRef94942" href="/d/graphic/94942.html" rel="external">table 1</a>). Abnormal HV should be evaluated even if the child has not developed tall stature.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Causes of abnormally rapid growth during infancy include maternal diabetes mellitus, cerebral gigantism (Sotos syndrome), and Beckwith-Wiedemann syndrome. (See <a class="local">'Statural overgrowth in infancy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Endocrine causes of abnormally rapid growth during childhood and adolescence include precocious puberty (including virilizing congenital adrenal hyperplasia), growth hormone excess (pituitary gigantism), hyperthyroidism, and familial glucocorticoid deficiency or resistance. (See <a class="local">'Statural overgrowth in childhood and adolescence'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Nonendocrine causes of abnormally rapid growth include Klinefelter syndrome and Marfan syndrome. Exogenous obesity is often associated with high-normal growth rates and relatively tall stature for age prior to puberty. However, bone age may be advanced so that adult height is not increased. A subset of patients with early onset obesity have pathogenic variants in the melanocortin 4 receptor (MC4R) and tend to have particularly tall stature as a child, which persists into adulthood. (See <a class="local">'Nonendocrine disorders'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Williams Textbook of Endocrinology, Wilson JD, Foster DW, Kronenberg HM, Larsen PR (Eds), Saunders, Philadelphia 1998. p.1427.</li><li><a class="nounderline abstract_t">Brook CG, Hindmarsh PC, Healy MJ. A better way to detect growth failure. Br Med J (Clin Res Ed) 1986; 293:1186.</a></li><li><a class="nounderline abstract_t">Nilsson O, Weise M, Landman EB, et al. Evidence that estrogen hastens epiphyseal fusion and cessation of longitudinal bone growth by irreversibly depleting the number of resting zone progenitor cells in female rabbits. Endocrinology 2014; 155:2892.</a></li><li><a class="nounderline abstract_t">Emons JA, Boersma B, Baron J, Wit JM. Catch-up growth: testing the hypothesis of delayed growth plate senescence in humans. J Pediatr 2005; 147:843.</a></li><li><a class="nounderline abstract_t">Sederquist B, Fernandez-Vojvodich P, Zaman F, Sävendahl L. Recent research on the growth plate: Impact of inflammatory cytokines on longitudinal bone growth. J Mol Endocrinol 2014; 53:T35.</a></li><li><a class="nounderline abstract_t">Hannema SE, van Duyvenvoorde HA, Premsler T, et al. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. J Clin Endocrinol Metab 2013; 98:E1988.</a></li><li><a class="nounderline abstract_t">Miura K, Kim OH, Lee HR, et al. Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am J Med Genet A 2014; 164A:156.</a></li><li><a class="nounderline abstract_t">Toydemir RM, Brassington AE, Bayrak-Toydemir P, et al. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet 2006; 79:935.</a></li><li><a class="nounderline abstract_t">Makrythanasis P, Temtamy S, Aglan MS, et al. A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly. Hum Mutat 2014; 35:959.</a></li><li><a class="nounderline abstract_t">Sotos JF. Sotos syndrome 1 and 2. Pediatr Endocrinol Rev 2014; 12:2.</a></li><li><a class="nounderline abstract_t">Gibson WT, Hood RL, Zhan SH, et al. Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet 2012; 90:110.</a></li><li><a class="nounderline abstract_t">Tatton-Brown K, Seal S, Ruark E, et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat Genet 2014; 46:385.</a></li><li><a class="nounderline abstract_t">Tlemsani C, Luscan A, Leulliot N, et al. SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort. J Med Genet 2016.</a></li><li><a class="nounderline abstract_t">Sakai LY, Keene DR, Renard M, De Backer J. FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders. Gene 2016; 591:279.</a></li><li><a class="nounderline abstract_t">Lauffer P, Kamp GA, Menke LA, et al. Towards a Rational and Efficient Diagnostic Approach in Children Referred for Tall Stature and/or Accelerated Growth to the General Paediatrician. Horm Res Paediatr 2019; 91:293.</a></li><li><a class="nounderline abstract_t">van Dommelen P, van Zoonen R, Vlasblom E, et al. Guideline for referring short or tall children in preventive child health care. Acta Paediatr 2021; 110:1231.</a></li><li><a class="nounderline abstract_t">Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocr Rev 1998; 19:540.</a></li><li><a class="nounderline abstract_t">Miller BS, Sarafoglou K, Addo OY. Development of Tanner Stage-Age Adjusted CDC Height Curves for Research and Clinical Applications. J Endocr Soc 2020; 4:bvaa098.</a></li><li><a class="nounderline abstract_t">Persson M, Pasupathy D, Hanson U, Norman M. Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study. Diabetes Care 2011; 34:1145.</a></li><li class="breakAll">Blizzard RM, Johanson A. Disorders of growth. In: The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, Kappy MS, Blizzard RM, Migeon CJ (Eds), Thomas, Illinois 1994.</li><li><a class="nounderline abstract_t">Barnes-Powell LL. Infants of diabetic mothers: the effects of hyperglycemia on the fetus and neonate. Neonatal Netw 2007; 26:283.</a></li><li><a class="nounderline abstract_t">Sotos JF, Cutler EA, Dodre P. Cerebral gigantism. Am J Dis Child 1977; 131:625.</a></li><li><a class="nounderline abstract_t">Agwu JC, Shaw NJ, Kirk J, et al. Growth in Sotos syndrome. Arch Dis Child 1999; 80:339.</a></li><li><a class="nounderline abstract_t">Lane C, Milne E, Freeth M. The cognitive profile of Sotos syndrome. J Neuropsychol 2019; 13:240.</a></li><li><a class="nounderline abstract_t">Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002; 30:365.</a></li><li><a class="nounderline abstract_t">Weng EY, Moeschler JB, Graham JM Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. Am J Med Genet 1995; 56:366.</a></li><li><a class="nounderline abstract_t">Sippell WG, Partsch CJ, Wiedemann HR. Growth, bone maturation and pubertal development in children with the EMG-syndrome. Clin Genet 1989; 35:20.</a></li><li><a class="nounderline abstract_t">Duffy KA, Cielo CM, Cohen JL, et al. Characterization of the Beckwith-Wiedemann spectrum: Diagnosis and management. Am J Med Genet C Semin Med Genet 2019; 181:693.</a></li><li><a class="nounderline abstract_t">Brioude F, Kalish JM, Mussa A, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol 2018; 14:229.</a></li><li><a class="nounderline abstract_t">Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2010; 154C:343.</a></li><li><a class="nounderline abstract_t">Priolo M, Schanze D, Tatton-Brown K, et al. Further delineation of Malan syndrome. Hum Mutat 2018; 39:1226.</a></li><li class="breakAll">University of California Los Angeles, Department of Human Genetics. Available at: http://labs.genetics.ucla.edu/martinez-agosto/cover.html (Accessed on April 30, 2014).</li><li><a class="nounderline abstract_t">Thomsett MJ. Referrals for tall stature in children: a 25-year personal experience. J Paediatr Child Health 2009; 45:58.</a></li><li><a class="nounderline abstract_t">Rayner JA, Pyett P, Astbury J. The medicalisation of 'tall' girls: A discourse analysis of medical literature on the use of synthetic oestrogen to reduce female height. Soc Sci Med 2010; 71:1076.</a></li><li><a class="nounderline abstract_t">Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004; 364:1513.</a></li><li><a class="nounderline abstract_t">Bruinsma FJ, Venn AJ, Patton GC, et al. Concern about tall stature during adolescence and depression in later life. J Affect Disord 2006; 91:145.</a></li><li><a class="nounderline abstract_t">Wettenhall HN, Cahill C, Roche AF. Tall girls: a survey of 15 years of management and treatment. J Pediatr 1975; 86:602.</a></li><li><a class="nounderline abstract_t">Prader A, Zachmann M. Treatment of excessively tall girls and boys with sex hormones. Pediatrics 1978; 62:1202.</a></li><li><a class="nounderline abstract_t">Bailey JD, Park E, Cowell C. Estrogen treatment of girls and constitutional tall stature. Pediatr Clin North Am 1981; 28:501.</a></li><li><a class="nounderline abstract_t">Pyett P, Rayner J, Venn A, et al. Using hormone treatment to reduce the adult height of tall girls: are women satisfied with the decision in later years? Soc Sci Med 2005; 61:1629.</a></li><li><a class="nounderline abstract_t">Bierich JR. Estrogen treatment of girls with constitutional tall stature. Pediatrics 1978; 62:1196.</a></li><li><a class="nounderline abstract_t">Sorgo W, Scholler K, Heinze F, et al. Critical analysis of height reduction in oestrogen-treated tall girls. Eur J Pediatr 1984; 142:260.</a></li><li><a class="nounderline abstract_t">Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056.</a></li><li><a class="nounderline abstract_t">Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689.</a></li><li><a class="nounderline abstract_t">Frank GR. The role of estrogen in pubertal skeletal physiology: epiphyseal maturation and mineralization of the skeleton. Acta Paediatr 1995; 84:627.</a></li><li><a class="nounderline abstract_t">Zachmann M, Ferrandez A, Můrset G, Prader A. Estrogen treatment of excessively tall girls. Helv Paediatr Acta 1975; 30:11.</a></li><li><a class="nounderline abstract_t">de Waal WJ, Greyn-Fokker MH, Stijnen T, et al. Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. J Clin Endocrinol Metab 1996; 81:1206.</a></li><li><a class="nounderline abstract_t">Joss EE, Temperli R, Mullis PE. Adult height in constitutionally tall stature: accuracy of five different height prediction methods. Arch Dis Child 1992; 67:1357.</a></li><li><a class="nounderline abstract_t">Upners EN, Juul A. Evaluation and phenotypic characteristics of 293 Danish girls with tall stature: effects of oral administration of natural 17β-estradiol. Pediatr Res 2016; 80:693.</a></li><li><a class="nounderline abstract_t">Hendriks AE, Drop SL, Laven JS, Boot AM. Fertility of tall girls treated with high-dose estrogen, a dose-response relationship. J Clin Endocrinol Metab 2012; 97:3107.</a></li><li><a class="nounderline abstract_t">Hannema SE, Sävendahl L. The Evaluation and Management of Tall Stature. Horm Res Paediatr 2016; 85:347.</a></li><li><a class="nounderline abstract_t">Reinehr T, Gueldensupp M, Wunsch R, Bramswig JH. Treatment of tall stature in boys: comparison of two different treatment regimens. Horm Res Paediatr 2011; 76:343.</a></li><li><a class="nounderline abstract_t">Goedegebuure WJ, Jonkers F, Boot AM, et al. Long-term follow-up after bilateral percutaneous epiphysiodesis around the knee to reduce excessive predicted final height. Arch Dis Child 2018; 103:219.</a></li><li><a class="nounderline abstract_t">Klein KO. Precocious puberty: who has it? Who should be treated? J Clin Endocrinol Metab 1999; 84:411.</a></li><li><a class="nounderline abstract_t">Schlesinger S, MacGillivray MH, Munschauer RW. Acceleration of growth and bone maturation in childhood thyrotoxicosis. J Pediatr 1973; 83:233.</a></li><li><a class="nounderline abstract_t">Sotos JF. Overgrowth. Hormonal Causes. Clin Pediatr (Phila) 1996; 35:579.</a></li><li><a class="nounderline abstract_t">Thistlethwaite D, Darling JA, Fraser R, et al. Familial glucocorticoid deficiency. Studies of diagnosis and pathogenesis. Arch Dis Child 1975; 50:291.</a></li><li><a class="nounderline abstract_t">Tsigos C, Arai K, Hung W, Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 1993; 92:2458.</a></li><li><a class="nounderline abstract_t">Pons Fernández N, Moriano Gutiérrez A, Taberner Pazos B, et al. A novel mutation in the NNT gene causing familial glucocorticoid deficiency, with a literature review. Ann Endocrinol (Paris) 2023.</a></li><li><a class="nounderline abstract_t">Coulter JB, Diver MJ, Isherwood DM, et al. Tall stature in isolated glucocorticoid deficiency: A case report and review of the literature. J Pediatr Endocrinol 1991; 4:271.</a></li><li><a class="nounderline abstract_t">Chung TT, Chan LF, Metherell LA, Clark AJ. Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2. Clin Endocrinol (Oxf) 2010; 72:589.</a></li><li><a class="nounderline abstract_t">van Rossum EF, Lamberts SW. Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab 2006; 20:611.</a></li><li><a class="nounderline abstract_t">Craveiro Sarmento AS, Ferreira LC, Lima JG, et al. The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy. Mutat Res Rev Mutat Res 2019; 781:30.</a></li><li><a class="nounderline abstract_t">SEIP M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr 1959; 48:555.</a></li><li><a class="nounderline abstract_t">Huseman C, Johanson A, Varma M, Blizzard RM. Congenital lipodystrophy: An endocrine study in three siblings. I. Disorders of carbohydrate metabolism. J Pediatr 1978; 93:221.</a></li><li><a class="nounderline abstract_t">Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009; 1791:507.</a></li><li><a class="nounderline abstract_t">Forbes GB. Nutrition and growth. J Pediatr 1977; 91:40.</a></li><li><a class="nounderline abstract_t">Biro FM, Khoury P, Morrison JA. Influence of obesity on timing of puberty. Int J Androl 2006; 29:272.</a></li><li><a class="nounderline abstract_t">Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev 2006; 27:710.</a></li><li><a class="nounderline abstract_t">Martinelli CE, Keogh JM, Greenfield JR, et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab 2011; 96:E181.</a></li><li><a class="nounderline abstract_t">Samango-Sprouse CA, Counts DR, Tran SL, et al. Update On The Clinical Perspectives And Care Of The Child With 47,XXY (Klinefelter Syndrome). Appl Clin Genet 2019; 12:191.</a></li><li><a class="nounderline abstract_t">Butler G, Srirangalingam U, Faithfull J, et al. Klinefelter syndrome: going beyond the diagnosis. Arch Dis Child 2023; 108:166.</a></li><li><a class="nounderline abstract_t">Ridder LO, Berglund A, Stochholm K, et al. Morbidity, mortality, and socioeconomics in Klinefelter syndrome and 47,XYY syndrome: a comparative review. Endocr Connect 2023; 12.</a></li><li><a class="nounderline abstract_t">Bardsley MZ, Kowal K, Levy C, et al. 47,XYY syndrome: clinical phenotype and timing of ascertainment. J Pediatr 2013; 163:1085.</a></li><li><a class="nounderline abstract_t">Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352:337.</a></li><li><a class="nounderline abstract_t">Hayward C, Porteous ME, Brock DJ. Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: report of 12 novel mutations. Hum Mutat 1997; 10:280.</a></li><li><a class="nounderline abstract_t">Morris AA, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 2017; 40:49.</a></li><li><a class="nounderline abstract_t">McCaddon A, Miller JW. Homocysteine-a retrospective and prospective appraisal. Front Nutr 2023; 10:1179807.</a></li><li><a class="nounderline abstract_t">Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1.</a></li><li class="breakAll">GeneReviews: Homocystinuria caused by cystathionine beta-synthase deficiency. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1524/ (Accessed on November 29, 2016).</li><li><a class="nounderline abstract_t">Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44:81.</a></li><li><a class="nounderline abstract_t">Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999; 103:1257.</a></li><li><a class="nounderline abstract_t">Josefson J, Listernick R, Fangusaro JR, et al. Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors. J Pediatr 2011; 158:433.</a></li></ol></div><div id="topicVersionRevision">Topic 5848 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Williams Textbook of Endocrinology, Wilson JD, Foster DW, Kronenberg HM, Larsen PR (Eds), Saunders, Philadelphia 1998. p.1427.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3096421" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A better way to detect growth failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708243" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence that estrogen hastens epiphyseal fusion and cessation of longitudinal bone growth by irreversibly depleting the number of resting zone progenitor cells in female rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16356444" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Catch-up growth: testing the hypothesis of delayed growth plate senescence in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24711646" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recent research on the growth plate: Impact of inflammatory cytokines on longitudinal bone growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24057292" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259409" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17033969" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24864036" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25345081" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sotos syndrome 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177091" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mutations in EZH2 cause Weaver syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27317772" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27437668" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302655" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Towards a Rational and Efficient Diagnostic Approach in Children Referred for Tall Stature and/or Accelerated Growth to the General Paediatrician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33118654" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Guideline for referring short or tall children in preventive child health care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9793756" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sex steroid treatment of constitutionally tall stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818164" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Development of Tanner Stage-Age Adjusted CDC Height Curves for Research and Clinical Applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430084" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430084" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17926658" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Infants of diabetic mothers: the effects of hyperglycemia on the fetus and neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/868814" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cerebral gigantism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086939" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Growth in Sotos syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336120" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The cognitive profile of Sotos syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896389" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Haploinsufficiency of NSD1 causes Sotos syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7541608" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924431" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Growth, bone maturation and pubertal development in children with the EMG-syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31469230" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Characterization of the Beckwith-Wiedemann spectrum: Diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29377879" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803657" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Beckwith-Wiedemann syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897170" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Further delineation of Malan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897170" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Further delineation of Malan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208068" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Referrals for tall stature in children: a 25-year personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20678835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The medicalisation of 'tall' girls: A discourse analysis of medical literature on the use of synthetic oestrogen to reduce female height.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15500896" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458977" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Concern about tall stature during adolescence and depression in later life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/165277" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tall girls: a survey of 15 years of management and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/214750" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of excessively tall girls and boys with sex hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7243375" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Estrogen treatment of girls and constitutional tall stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029770" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Using hormone treatment to reduce the adult height of tall girls: are women satisfied with the decision in later years?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/214749" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Estrogen treatment of girls with constitutional tall stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6092088" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Critical analysis of height reduction in oestrogen-treated tall girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090165" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8530621" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7670243" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The role of estrogen in pubertal skeletal physiology: epiphyseal maturation and mineralization of the skeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/169220" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Estrogen treatment of excessively tall girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772601" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1471886" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adult height in constitutionally tall stature: accuracy of five different height prediction methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27410906" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation and phenotypic characteristics of 293 Danish girls with tall stature: effects of oral administration of natural 17β-estradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723330" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fertility of tall girls treated with high-dose estrogen, a dose-response relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26845047" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Evaluation and Management of Tall Stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22024831" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of tall stature in boys: comparison of two different treatment regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030385" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term follow-up after bilateral percutaneous epiphysiodesis around the knee to reduce excessive predicted final height.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022393" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Precocious puberty: who has it? Who should be treated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4352207" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acceleration of growth and bone maturation in childhood thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8953133" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Overgrowth. Hormonal Causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/238474" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Familial glucocorticoid deficiency. Studies of diagnosis and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227361" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37352919" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A novel mutation in the NNT gene causing familial glucocorticoid deficiency, with a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tall stature in isolated glucocorticoid deficiency: A case report and review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19558534" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161335" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31416577" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14444642" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/209163" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Congenital lipodystrophy: An endocrine study in three siblings. I. Disorders of carbohydrate metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19162222" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lipodystrophies: disorders of adipose tissue biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/874662" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nutrition and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371114" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Influence of obesity on timing of puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122358" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Genetics of obesity in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047921" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31695472" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Update On The Clinical Perspectives And Care Of The Child With 47,XXY (Klinefelter Syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948402" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Klinefelter syndrome: going beyond the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37098811" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Morbidity, mortality, and socioeconomics in Klinefelter syndrome and 47,XYY syndrome: a comparative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23810129" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : 47,XYY syndrome: clinical phenotype and timing of ascertainment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852208" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9338581" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: report of 12 novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27778219" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37384104" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Homocysteine-a retrospective and prospective appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872065" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The natural history of homocystinuria due to cystathionine beta-synthase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872065" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The natural history of homocystinuria due to cystathionine beta-synthase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105749" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10353939" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030036" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
